Keyphrases
Glioblastoma
100%
T Cells
100%
Antitumor Activity
100%
Safety Activity
100%
Chimeric Antigen Receptor T Cells (CAR-T)
28%
Antigen Loss
28%
Tumor
14%
Immune Response
14%
Trial Registration
14%
Intravenous Administration
14%
Median Overall Survival
14%
Peripheral Blood
14%
Tumor Microenvironment
14%
Intracavitary
14%
Stable Disease
14%
Severe Adverse Events
14%
Anti-glioblastoma
14%
Partial Response
14%
Progressive Disease
14%
Medicine and Dentistry
Glioblastoma
100%
Antineoplastic Activity
100%
T Cell
100%
Infusion
71%
Adverse Event
14%
Neoplasm
14%
Immune Response
14%
Overall Survival
14%
Tumor Microenvironment
14%
Chimeric Antigen Receptor
14%
Chimeric Antigen Receptor T-Cell
14%
Intracavitary Drug Administration
14%
Progressive Disease
14%
Diseases
14%
Biochemistry, Genetics and Molecular Biology
GD2
100%
Antineoplastic Activity
100%
T Cell
100%
Immune Response
12%
Chimeric Antigen Receptor
12%
Overall Survival
12%
Immunology and Microbiology
Antineoplastic Activity
100%
T Cell
100%
Immune Response
14%
Chimeric Antigen Receptor
14%
Chimeric Antigen Receptor T-Cell
14%
Overall Survival
14%